Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

Medicine, Endocrinology, Oncology +11

<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

Mingzhao Xing, Rengyun Liu, Xiaoli Liu et al. · Journal of Clinical Oncology · 2014 · 715 citations · Full text

Medicine, Genetics, Oncology +15

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research · 2014 · 480 citations · Full text

Medicine, Oncology, Pharmacology +17